1. The subject of the contract is the supply of medicinal products from drug programs (increase in the value of NFZ 140000774230019 and NFZ 140000774230001 contracts of 16.06.2023. programs: Treatment of chronic lymphocytic leukemia, Treatment of patients with multiple myeloma, Treatment of ulcerative colitis, Treatment of nephropathic cystinosis, Treatment of autosomal dominant polycystic degeneration of the kidney and supply of antibiotics introduced by the decision of the Committee Therapeutic to the Hospital Formulary in accordance with the NPOA Recommendations 2022, (Enterobacterales bacilli producing carbapenemases - treatment and prevention of infections) after 3 treatments, other drugs introduced into the Hospital Formulary, in addition, a tender supplementing infusion fluids for 6 months, cytotoxic drugs from the chemotherapy catalog, other drugs.

Filgotinibum

Orytawacyna

Erythromycin

Infusion fluids

Aztreonam

Complete diet in terms of nutrition, high energy, normoprotein

Complete diet in terms of nutrition, high energy, high protein

Complete diet in terms of nutrition

Diet supporting the treatment of wounds and bedsores

Powder and solvent kit for tissue adhesive

Clonazepam, Zofenopryl, Paracetamol, Kabergolina

DARATUMUMABUM

Dacarbazinum, Doxorubicinum liposomal, Methotrexatum, Irinotecani

Vedolizumabum

Filgotinibum

Mercaptamini bitartras

Mercaptamini hydrochloridum

Tolvaptanum

Iron ( iron derisomaltosis III )

Propofol, Biwalirudyna